A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine
NCT04437433
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
186
Enrollment
INDUSTRY
Sponsor class
Conditions
Chronic Migraine
Episodic Migraine
Interventions
DRUG:
Atogepant 60 mg
Sponsor
AbbVie